IgA Nephropathy (Berger's Disease) Global Clinical Trials Review 2024, by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

2024-03-12

临床研究

DUBLIN, March 12, 2024 /PRNewswire/ -- The "IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2024" clinical trials has been added to

ResearchAndMarkets.com's offering.

The clinical trial report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type and also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Report Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Key Benefits

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Countries Contributing to Clinical Trials in Middle East and Africa

Top Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of IgA Nephropathy (Berger's Disease) to Genito Urinary System Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of IgA Nephropathy (Berger's Disease) to Genito Urinary System Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in IgA Nephropathy (Berger's Disease) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Company Coverage:

Novartis

AstraZeneca

Calliditas Therapeutics

Jiangsu Hengrui Medicine

Patient Square Capital

Travere Therapeutics

IQVIA Holdings

Otsuka Holdings

Thermo Fisher Scientific

F. Hoffmann-La Roche

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/gdcv1x

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets